Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC is critically appraising manufacturer’s submission to NICE on new drug for type 2 diabetes

Published: 4 November 2013

SHTAC is assessing the clinical-effectiveness and cost-effectiveness of canagliflozin for the treatment of type 2 diabetes for the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal process.

Diabetes mellitus is a chronic metabolic disorder characterised by elevated blood glucose levels (hyperglycaemia) resulting from a lack of the hormone insulin or resistance to its action. In the UK, about 90% of all adults with diabetes have type 2 diabetes. The UK prevalence of type 2 diabetes is rising because of increased prevalence of obesity, decreased physical activity and increased life expectancy after diagnosis because of better cardiovascular risk protection.

Canagliflozin (‘Invokana', Janssen-Cilag) is classed as a ‘selective sodium glucose-cotransporter 2' (SGLT-2) inhibitor which blocks the reabsorption of glucose in the kidneys and promotes excretion of excess glucose in the urine. Canagliflozin is intended to be used in combination with other oral anti-diabetic agents and/or insulin.

NICE is expected to issue guidance to the health service in England and Wales on canagliflozin in April 2014.

For more information on SHTAC's research into diabetes please visit our Research page.

Privacy Settings